# GE HealthCare **Source:** https://geo.sig.ai/brands/ge-healthcare **Vertical:** Healthcare Tech **Subcategory:** Enterprise **Tier:** Leader **Website:** ge-healthcare.com **Last Updated:** 2026-04-14 ## Summary Chicago medical imaging and AI diagnostics (NASDAQ: GEHC) ~$19.7B FY2024 revenue; GE spinoff Jan 2023, Edison AI 100+ models, 4M+ installed devices, Alzheimer's PET tracer competing with Siemens Healthineers. ## Company Overview GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designing, manufacturing, and servicing medical imaging systems, patient monitoring equipment, pharmaceutical diagnostics, and AI-powered clinical decision support software through approximately 51,000 employees in 160 countries. GE HealthCare was spun off from General Electric Company in January 2023 — one of the most significant healthcare demergers in history — and has operated as an independent public company building its own capital structure, R&D investment priorities, and operational identity separate from GE's industrial conglomerate structure. In fiscal year 2024, GE HealthCare reported revenues of approximately $19.7 billion, with its four business segments contributing: Imaging (MRI, CT, X-ray, molecular imaging — ~$9.1B), Ultrasound (~$3.0B), Patient Care Solutions (monitoring, anesthesia — ~$3.6B), and Pharmaceutical Diagnostics (PET/SPECT contrast agents — ~$2.6B). CEO Peter Arduini has prioritized accelerating GE HealthCare's AI integration across its imaging portfolio — the Edison AI platform (100+ AI models cleared or in development for radiology workflows) embeds AI-assisted detection, workflow optimization, and image quality enhancement into GE HealthCare scanners, positioning the company as a digital health platform rather than a hardware manufacturer. GE HealthCare's medical technology and digital health model creates competitive advantages through the combination of deep OEM imaging system installed base (over 4 million GE HealthCare devices installed in hospitals worldwide) and the AI enhancement layer that differentiates scanner performance and clinical workflow: a hospital radiology department running 40 GE HealthCare CT scanners generates tens of millions of scan images per year flowing through GE HealthCare's Edison AI models (Auto Lung Analysis, DL Recon image reconstruction, Critical Care Suite abnormality detection) — creating a data flywheel where more scans improve AI model performance, which justifies premium pricing for the AI-enabled scanner configurations. The Pharmaceutical Diagnostics segment (contrast agents for PET, SPECT, and MRI imaging — Vizamyl for amyloid PET imaging in Alzheimer's disease, Definity ultrasound contrast) creates recurring consumable revenue tied to imaging procedure volumes that are growing as aging populations increase diagnostic imaging utilization. GE HealthCare's service and support contracts (multi-year service agreements for scanner maintenance, software updates, and clinical training) generate predictable recurring revenue across the 4 million+ installed device base. In 2025, GE HealthCare competes in medical imaging, patient monitoring, and AI diagnostics against Siemens Healthineers (ETR: SHL, €22B revenue, MRI/CT leadership), Philips Healthcare (AMS: PHIA, €17B revenue, ultrasound and patient monitoring), and Canon Medical Systems (private, Japanese CT and ultrasound) for hospital imaging system procurement, AI radiology platform contracts, and pharmaceutical diagnostics supply agreements. The Alzheimer's disease diagnostic imaging opportunity — Leqembi (lecanemab) and donanemab amyloid-clearing therapy approvals requiring amyloid PET scans to confirm patient eligibility — creates structural demand growth for GE HealthCare's Vizamyl amyloid PET tracer and PET scanner configurations as neurologists screen patients for anti-amyloid therapy eligibility. The AI radiology platform competition (Siemens AI-Rad Companion, Philips IntelliSpace AI, Nuance PowerScribe AI workflow) drives differentiation investment as hospital IT buyers evaluate AI workflow value alongside hardware specifications. The 2025 strategy focuses on Edison AI model expansion (cardiovascular AI, oncology imaging AI), Pharmaceutical Diagnostics volume growth from Alzheimer's therapy patient screening, and service contract renewal optimization across the global installed base. ## Frequently Asked Questions ### What does GE HealthCare do? GE HealthCare is a leading global medical technology and digital solutions company providing precision care technologies including medical imaging (CT, MRI, ultrasound, X-ray), patient monitoring systems, pharmaceutical diagnostics, and AI-powered healthcare solutions. The company serves healthcare providers in more than 160 countries with an installed base of over 4 million pieces of equipment, treating over one billion patients annually and generating $19.7 billion in annual revenue. ### When was GE HealthCare founded? GE HealthCare launched as an independent public company on January 4, 2023, when it spun off from General Electric. However, the company's healthcare lineage dates back to 1893 with the founding of Victor Electric Company, and GE's entry into medical equipment in 1896. GE formally incorporated its healthcare division in 1994, creating over a century of medical innovation history. ### Where is GE HealthCare headquartered? GE HealthCare is headquartered in Chicago, Illinois, United States. The company operates globally in more than 160 countries with manufacturing facilities, R&D centers, and service operations worldwide, including significant presences in Europe, Asia, and the Americas. ### Who is the CEO of GE HealthCare? Peter J. Arduini serves as President and Chief Executive Officer of GE HealthCare. He was appointed in December 2022 in connection with the company's spin-off from General Electric. Arduini previously served as President and CEO of Integra LifeSciences from 2012 to 2021, and serves on the board of Bristol Myers Squibb and chairs AdvaMed's board of directors. ### What are GE HealthCare's main products? GE HealthCare's main products include advanced medical imaging systems (Photonova Spectra photon counting CT, Freelium helium-free MRI, Pristina Recon DL mammography), ultrasound systems (LOGIQ, Voluson, Vscan Air), patient monitoring and care solutions, pharmaceutical diagnostics (Flyrcado PET imaging agent, contrast media), and AI-powered digital health platforms like CareIntellect for Oncology. The company operates through four divisions: Medical Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. ### How many employees does GE HealthCare have? GE HealthCare has approximately 53,000 employees as of December 2024, representing a 3.92% increase from the previous year. The workforce spans more than 160 countries, supporting global healthcare providers with manufacturing, R&D, clinical support, and service operations. ### What makes GE HealthCare different from competitors? GE HealthCare differentiates itself through industry-leading AI innovation (most FDA-authorized AI-enabled devices of any medical technology company), pioneering photon counting CT technology with Deep Silicon detectors, breakthrough helium-free MRI systems, an installed base of 4+ million pieces of equipment creating strong service revenue, over $1.3 billion in annual R&D investment, and comprehensive portfolio spanning imaging, diagnostics, monitoring, and digital solutions. The company's vision for precision care and early health model sets it apart strategically. ### Who are GE HealthCare's main competitors? GE HealthCare's primary competitors include Siemens Healthineers (imaging and diagnostics), Philips Healthcare (imaging and patient monitoring), Canon Medical Systems (imaging), Fujifilm Healthcare (imaging), Hologic (women's health imaging), and various specialized competitors in ultrasound, patient monitoring, and pharmaceutical diagnostics. The competitive landscape varies by product segment and geographic region. ### What was GE HealthCare's financial performance in 2024? GE HealthCare reported strong 2024 results with full-year revenue of $19.7 billion (up 1% year-over-year), adjusted EBIT margin of 16.3% (up from 15.1%), net income margin of 10.1% (up from 8.0%), and orders growth of 3% organically. The company invested over $1.3 billion in R&D and maintained a book-to-bill ratio of 1.05 times. For 2025, the company projects 2-3% organic revenue growth with continued margin expansion. ### Is GE HealthCare a publicly traded company? Yes, GE HealthCare is a publicly traded company that began trading independently on NASDAQ under ticker symbol GEHC on January 4, 2023, following its spin-off from General Electric. The company has a market capitalization exceeding $36 billion, with General Electric retaining approximately 19.9% ownership stake. ### What is GE HealthCare's market position? GE HealthCare is a global leader in medical imaging with significant market share across CT, MRI, ultrasound, and X-ray systems. The company maintains the industry's largest installed base with over 4 million pieces of equipment worldwide, serves healthcare providers in 160+ countries treating one billion patients annually, and leads the medical device industry in FDA-authorized AI innovations. With $19.7 billion in revenue and strong margins, GE HealthCare is positioned among the top three medical technology companies globally. ### What are GE HealthCare's innovation and sustainability initiatives? GE HealthCare is pioneering innovations in AI-powered diagnostics (leading FDA authorizations), photon counting CT with Deep Silicon technology, helium-free MRI systems addressing global shortages, deep-learning mammography for earlier cancer detection, first-in-class PET imaging agents, and generative AI platforms like CareIntellect. The company's vision focuses on enabling an early health model of care through earlier diagnosis, pre-symptomatic disease detection, and disease prevention, supported by over $1.3 billion in annual R&D investment. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*